Trial
NCT03929211
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI)
Condition
Myelodysplastic Syndromes
Intervention
CPI-613
Why stopped
Administrative withdrawal by IRB
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-14